心臓バイオマーカー市場：タイプ、検査部位、用途別-2025-2030年の世界予測

心臓バイオマーカー市場は、2023年に46億2,000万米ドルと評価され、2024年には53億1,000万米ドルに達すると予測され、CAGR 14.90％で成長し、2030年には122億4,000万米ドルに達すると予測されています。

心臓バイオマーカーは、急性冠症候群や心不全などの心臓疾患の検出と評価に使用される重要な診断ツールです。これらのバイオマーカーは、心臓が損傷したときに血液中に放出されるタンパク質や酵素であり、状態の重症度に関する洞察を提供します。心臓バイオマーカーの必要性は、その非侵襲的な性質にあり、心臓関連疾患の早期介入と管理に極めて重要な迅速で信頼性の高い診断情報を提供します。心臓バイオマーカーは、診断、リスク層別化、治療計画の指針として臨床現場で広く利用されています。主なエンドユーザーは、病院、診断研究所、心血管研究に積極的に取り組んでいる研究機関などです。

心臓バイオマーカー市場は、心血管疾患の有病率の上昇、ポイントオブケア検査に対する需要の増加、バイオマーカーの発見と検証の進歩などの要因により、成長の呼び水となっています。新たなビジネスチャンスとしては、感度と特異度を向上させる新規バイオマーカーの開発、遠隔モニタリングとタイムリーな介入を促進するデジタルヘルスソリューションの普及などが挙げられます。企業に対する主な提言は、従来のバイオマーカーと新規バイオマーカーの両方を網羅する統合検査ソリューションを革新し提供するために、共同研究開発に注力することです。

しかし、市場はバイオマーカー探索に関連する高コストや、製品開発スケジュールを長期化させる厳しい規制要件などの制約に直面しています。さらに、患者集団によってバイオマーカー値にばらつきがあるため、バイオマーカーに基づくアッセイの臨床的有用性と商業化が困難となる可能性があります。

人工知能と機械学習を統合してバイオマーカー解析と解釈を強化することや、包括的な心臓診断を提供するマルチプレックスアッセイを開発することには、イノベーションの機会が豊富にあります。バイオマーカー産生の遺伝的基盤に焦点を当てた調査は、個人の遺伝的プロファイルに合わせて診断ツールを調整することで精密医療を実現し、将来の市場成長を促進する可能性があります。市場競争は依然として続いており、総合的な心臓健康モニタリング・システムへの取り組みが、包括的な疾病管理ソリューションに有望な道を提供しています。

市場力学：急速に進化する心臓バイオマーカー市場の主要市場インサイトを公開

心臓バイオマーカー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の心血管疾患の罹患率の増加
  • 心血管疾患の早期診断に対する認識と必要性の高まり
  • 老年人口と関連する心臓疾患の急増
• 市場抑制要因
  • サンプル採取と保存に関連する技術的問題
• 市場機会
  • 心臓バイオマーカーの研究開発活動への投資の増加
  • 心臓バイオマーカーを用いたPOC検査の需要の高まり
• 市場の課題
  • 規制と償還制度に対する懸念

ポーターの5つの力：心臓バイオマーカー市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：心臓バイオマーカー市場における外部からの影響の把握

外部マクロ環境要因は、心臓バイオマーカー市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析心臓バイオマーカー市場における競合情勢の把握

心臓バイオマーカー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス心臓バイオマーカー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、心臓バイオマーカー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨心臓バイオマーカー市場における成功への道筋を描く

心臓バイオマーカー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で心血管疾患の発生率が増加
    • 心血管疾患の早期診断に対する意識と必要性の高まり
    • 高齢者人口の急増と関連する心臓病
  • 抑制要因
    • サンプルの収集と保管に関する技術的な問題
  • 機会
    • 心臓バイオマーカーの研究開発活動への新たな投資
    • 心臓バイオマーカーを用いたPOC検査の需要の高まり
  • 課題
    • 規制と償還制度に関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 心臓バイオマーカー市場：タイプ別

• 脳性ナトリウム利尿ペプチドまたはNT-proBNP
• クレアチンキナーゼ
• 虚血修飾アルブミン
• ミオグロビン
• トロポニン

第7章 心臓バイオマーカー市場試験場所別

• 臨床検査
• ポイントオブケア検査

第8章 心臓バイオマーカー市場：用途別

• 急性冠症候群
• 動脈硬化症
• うっ血性心不全
• 心筋梗塞

第9章 南北アメリカの心臓バイオマーカー市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の心臓バイオマーカー市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの心臓バイオマーカー市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Beckman Coulter, Inc.
• Becton, Dickinson and Company
• bioMerieux SA
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Guangzhou Wondfo Biotech Co., Ltd.
• Johnson & Johnson Services, Inc.
• Olympus Corporation
• PerkinElmer Inc.
• Quidel Corporation
• Randox Laboratories Ltd.
• Siemens Healthcare GmbH
• Thermo Fisher Scientific Inc.
• Tosoh Corporation

LIST OF FIGURES

• FIGURE 1. CARDIAC BIOMARKER MARKET RESEARCH PROCESS
• FIGURE 2. CARDIAC BIOMARKER MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CARDIAC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CARDIAC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CARDIAC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CARDIAC BIOMARKER MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CARDIAC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CARDIAC BIOMARKER MARKET DYNAMICS
• TABLE 7. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BRAIN NATRIURETIC PEPTIDE OR NT-PROBNP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CREATINE KINASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ISCHEMIA MODIFIED ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 33. CANADA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 50. CHINA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 53. INDIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 105. ITALY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 117. POLAND CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 120. QATAR CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. CARDIAC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. CARDIAC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023

The Cardiac Biomarker Market was valued at USD 4.62 billion in 2023, expected to reach USD 5.31 billion in 2024, and is projected to grow at a CAGR of 14.90%, to USD 12.24 billion by 2030.

Cardiac biomarkers are crucial diagnostic tools used for the detection and evaluation of heart conditions, including acute coronary syndrome and heart failure. These biomarkers are proteins or enzymes released into the blood when the heart is damaged, offering insights into the condition's severity. The necessity for cardiac biomarkers lies in their non-invasive nature, providing quick and reliable diagnostic information pivotal for early intervention and management of heart-related diseases. They are widely used in clinical settings for diagnosis, risk stratification, and as a measure to guide treatment plans. Major end-users include hospitals, diagnostic laboratories, and research institutions actively involved in cardiovascular studies.

The cardiac biomarker market is primed for growth due to factors such as the rising prevalence of cardiovascular diseases, increasing demand for point-of-care testing, and advancements in biomarker discovery and validation. Emerging opportunities include the development of novel biomarkers that offer enhanced sensitivity and specificity, coupled with the proliferation of digital health solutions that facilitate remote monitoring and timely intervention. A key recommendation for businesses is to focus on collaborative research and development to innovate and provide integrated testing solutions that encompass both traditional and novel biomarkers.

However, the market faces limitations like high costs associated with biomarker discovery and stringent regulatory requirements that lengthen product development timelines. Additionally, the variability in biomarker levels among different patient populations can challenge the clinical utility and commercialization of biomarker-based assays.

Innovation opportunities are abundant in the integration of artificial intelligence and machine learning to enhance biomarker analysis and interpretation, as well as in developing multiplex assays that provide comprehensive cardiac diagnostics. Research focusing on the genetic basis of biomarker production, implementing precision medicine by tailoring diagnostic tools to individual genetic profiles, can drive future market growth. The market remains competitive, with a push towards holistic cardiac health monitoring systems, offering a promising avenue for comprehensive disease management solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiac Biomarker Market

The Cardiac Biomarker Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing incidence of cardiovascular diseases globally
  • Increasing awareness and need for early diagnosis of cardiovascular diseases
  • Surge in geriatric population and related heart diseases
• Market Restraints
  • Technical issues pertinent to sample collection and storage
• Market Opportunities
  • Emerging investment in research and development activities in cardiac biomarkers
  • Emerging demand for POC testing with cardiac biomarkers
• Market Challenges
  • Concerns over regulatory and reimbursement systems

Porter's Five Forces: A Strategic Tool for Navigating the Cardiac Biomarker Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiac Biomarker Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiac Biomarker Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiac Biomarker Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiac Biomarker Market

A detailed market share analysis in the Cardiac Biomarker Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiac Biomarker Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiac Biomarker Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cardiac Biomarker Market

A strategic analysis of the Cardiac Biomarker Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Biomarker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, bioMerieux SA, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Guangzhou Wondfo Biotech Co., Ltd., Johnson & Johnson Services, Inc., Olympus Corporation, PerkinElmer Inc., Quidel Corporation, Randox Laboratories Ltd., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., and Tosoh Corporation.

Market Segmentation & Coverage

This research report categorizes the Cardiac Biomarker Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Brain Natriuretic Peptide or NT-proBNP, Creatine Kinase, Ischemia Modified Albumin, Myoglobin, and Troponins.
• Based on Location of Testing, market is studied across Laboratory Testing and Point of Care Testing.
• Based on Application, market is studied across Acute Coronary Syndrome, Atherosclerosis, Congestive Heart Failure, and Myocardial Infarction.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidence of cardiovascular diseases globally
    • 5.1.1.2. Increasing awareness and need for early diagnosis of cardiovascular diseases
    • 5.1.1.3. Surge in geriatric population and related heart diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Technical issues pertinent to sample collection and storage
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging investment in research and development activities in cardiac biomarkers
    • 5.1.3.2. Emerging demand for POC testing with cardiac biomarkers
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns over regulatory and reimbursement systems
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cardiac Biomarker Market, by Type

• 6.1. Introduction
• 6.2. Brain Natriuretic Peptide or NT-proBNP
• 6.3. Creatine Kinase
• 6.4. Ischemia Modified Albumin
• 6.5. Myoglobin
• 6.6. Troponins

7. Cardiac Biomarker Market, by Location of Testing

• 7.1. Introduction
• 7.2. Laboratory Testing
• 7.3. Point of Care Testing

8. Cardiac Biomarker Market, by Application

• 8.1. Introduction
• 8.2. Acute Coronary Syndrome
• 8.3. Atherosclerosis
• 8.4. Congestive Heart Failure
• 8.5. Myocardial Infarction

9. Americas Cardiac Biomarker Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cardiac Biomarker Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cardiac Biomarker Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Beckman Coulter, Inc.
• 3. Becton, Dickinson and Company
• 4. bioMerieux SA
• 5. DiaSorin S.p.A.
• 6. F. Hoffmann-La Roche Ltd.
• 7. Guangzhou Wondfo Biotech Co., Ltd.
• 8. Johnson & Johnson Services, Inc.
• 9. Olympus Corporation
• 10. PerkinElmer Inc.
• 11. Quidel Corporation
• 12. Randox Laboratories Ltd.
• 13. Siemens Healthcare GmbH
• 14. Thermo Fisher Scientific Inc.
• 15. Tosoh Corporation